Chimerix to Present at the Stifel 2018 Healthcare Conference

DURHAM, N.C., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Chimerix CMRX, a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H., Chief Executive Officer and Tim Trost, Chief Financial Officer will participate in a fireside chat at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 9:30 a.m. ET at the Lotte New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:

Investor Relations:

Michelle LaSpaluto

(919) 972-7115

ir@chimerix.com

or

Will O'Connor

Stern Investor Relations

Will@sternir.com  

(212) 362-1200

Media:

Laurie Masonson

W2O Group

lmasonson@w2ogroup.com

(917) 459-6164